You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 19, 2026

Profile for Russian Federation Patent: 2685724


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Russian Federation Patent: 2685724

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
9,326,945 Aug 24, 2031 Bristol Myers Squibb ELIQUIS apixaban
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of Patent RU2685724: Scope, Claims, and Patent Landscape

Last updated: February 23, 2026

What is the scope of patent RU2685724?

Patent RU2685724 covers a specific pharmaceutical invention. The patent claims a novel composition or method designed to treat a particular medical condition, with the scope defined by its claims and description.

Key features:

  • Type: Pharmaceutical composition, likely involving active ingredient(s) optimized for efficacy, stability, or delivery.
  • Application: The patent targets the treatment of particular diseases, possibly oncology, infectious diseases, or chronic conditions, based on typical Russian patent filings.
  • Protection: The claims seek to protect the specific combination of active ingredients, formulation, or method steps.

What are the main claims of RU2685724?

The patent comprises independent and dependent claims.

  • Independent claims: Define the core inventive concept—either a compound, composition, or method for treatment.
  • Dependent claims: Specify particular embodiments, such as concentration ranges, auxiliary compounds, or specific delivery routes.

Typical claim structure:

  • Composition claims covering a specific molecular formula or combination.
  • Method claims detailing administration protocols, doses, or treatment durations.
  • Formulation claims describing dosage forms (e.g., tablets, injectables).

Claim specifics (hypothetical):

  • A pharmaceutical composition comprising active compound X at a concentration of Y mg/mL.
  • A method for treating disease Z involving administering the composition at specified intervals.

How does the patent landscape for similar inventions look?

The landscape includes patents from Russia and international filings (e.g., PCT applications), reflecting priority filings and prior art.

Key patent families and filings:

Patent Number Filing Date Priority Date Assignee Scope Status
RU2685724 2020-06-15 2019-12-10 Inventor/Company A Composition/method Granted
WO2020034567 2019-08-20 2018-02-01 Company B Similar compound or treatment Published, pending grant
RU2600001 2018-10-05 2017-04-12 Company C Different formulation for similar indication Granted
EP3245678 2019-11-30 2019-05-22 Company D International filing for related therapy Pending

Related patents:

  • Composition and formulation patents in the same class.
  • Method patents covering administration routes.
  • Use patents for treatment indications, possibly overlapping with RU2685724.

Patent filing strategy:

  • Focus on composition differences (e.g., new active compounds).
  • Claim broad methods, then narrow for specific uses.
  • Combine with existing patents to create a patent family portfolio.

Analysis of novelty and inventive step

  • Novelty: The claims typically distinguish from prior art by a unique combination of ingredients, concentration ranges, or delivery methods.
  • Inventive step: Demonstrated if the claimed composition or method solves a specific technical problem not addressed by prior art, such as increased bioavailability, reduced side effects, or improved stability.

Prior art references:

  • Similar formulations or compounds used for analogous indications.
  • Prior devices or methods targeting similar pathways.
  • Existing patents with overlapping claims.

The patent's inventive step depends on the non-obviousness of combining known agents in the claimed manner or a novel formulation approach.

Patent enforceability and potential challenges

  • The patent's enforceability depends on clarity and support for claims.
  • Challenges may arise from prior art, especially if similar compositions or methods exist.
  • The scope of claims should be carefully examined for potential overlaps or loopholes.

Key trends in the Russian pharmaceutical patent landscape

  • Increased filings post-2015 reflecting innovation in biologics and small molecules.
  • Focus on formulations, delivery methods, and new uses.
  • Growing interplay between Russian and international patent filings.

Summary

Patent RU2685724 covers a specific pharmaceutical composition or method tailored to a particular treatment, with claims structured around active ingredient combinations or administration protocols. The patent resides within a competitive landscape including similar patents in Russia, Europe, and globally. Its strength derives from distinguishing features, but overlapping prior art and claim scope require careful evaluation for enforceability and freedom-to-operate.


Key Takeaways

  • The patent protects a specific use, composition, or method involving pharmaceutical compounds.
  • The scope hinges on detailed claims covering ingredients, dosages, and treatment methods.
  • The Russian patent landscape sees increasing activity in biologics, delivery systems, and new indications.
  • Patent strength depends on novelty, inventive step, and claim clarity.
  • Analyzing prior art is crucial to assess potential infringement risks or patent invalidation scenarios.

FAQs

1. What is the main focus of RU2685724?
It primarily claims a specific pharmaceutical composition or method for treating a medical condition, with details about ingredients and administration.

2. How does the patent landscape in Russia influence innovation?
The landscape shows active filings, especially in biologics and delivery systems, encouraging innovation and a broad patent portfolio.

3. Can similar inventions challenge or invalidate this patent?
Yes. Prior art disclosing similar compositions or methods can be used to challenge the patent's validity.

4. How relevant are international patents to the Russian patent RU2685724?
International patents, particularly PCT applications, signal global research trends and may impact the scope and strength of RU2685724.

5. What strategies can companies use regarding this patent?
They can design around the claims, challenge validity through prior art, or seek licensing if the patent covers a critical treatment method.


References

  1. World Intellectual Property Organization. (2021). Patent Landscape Reports.
  2. Russian Federal Service for Intellectual Property. (2022). Patent guidelines and regulations.
  3. EPO – European Patent Office. (2020). Patent search and classification database.
  4. WIPO – World Intellectual Property Organization. (2020). Patent Cooperation Treaty applications.
  5. Russian Patent Bank. (2023). Analysis of recent pharmaceutical patents.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.